Top Page
Atomo Diagnostics Ltd.
(Sydney:AT1)
Atomo Diagnostics Ltd. (AT1) vs. iShares MSCI Australia ETF (EWA)
Atomo Diagnostics Ltd. Business Overview & Revenue Model
Atomo Diagnostics Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.79M | 3.79M | 4.09M | 2.54M | 12.34M | 6.72M |
| Gross Profit | 1.79M | 1.79M | 1.44M | -6.08M | -1.85M | -1.71M |
| EBITDA | -4.69M | -4.69M | -6.12M | -9.00M | -4.72M | -4.70M |
| Net Income | -4.97M | -4.97M | -6.85M | -9.96M | -5.71M | -6.02M |
Balance Sheet | ||||||
| Total Assets | 9.28M | 9.28M | 11.38M | 16.47M | 26.62M | 32.24M |
| Cash, Cash Equivalents and Short-Term Investments | 3.22M | 3.22M | 3.69M | 6.47M | 12.97M | 17.95M |
| Total Debt | 185.10K | 185.10K | 84.67K | 254.88K | 340.81K | 67.59K |
| Total Liabilities | 2.30M | 2.30M | 1.29M | 1.68M | 1.81M | 2.15M |
| Stockholders Equity | 6.98M | 6.98M | 10.08M | 14.79M | 24.81M | 30.09M |
Cash Flow | ||||||
| Free Cash Flow | -1.99M | -1.99M | -4.70M | -6.25M | -5.11M | -10.12M |
| Operating Cash Flow | -1.96M | -1.96M | -4.69M | -5.85M | -2.81M | -4.23M |
| Investing Cash Flow | -33.89K | -33.89K | -16.08K | -401.28K | -2.31M | -5.90M |
| Financing Cash Flow | 1.46M | 1.46M | 1.87M | -170.75K | 17.61K | 997.37K |
Atomo Diagnostics Ltd. Technical Analysis
Atomo Diagnostics Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$25.54M | -2.66 | -103.74% | ― | 14.84% | 39.64% | |
48 Neutral | AU$30.79M | -4.94 | -58.27% | ― | -7.20% | 28.70% | |
43 Neutral | AU$46.02M | -8.27 | -513.22% | ― | -34.06% | 75.47% | |
42 Neutral | AU$6.16M | -4.03 | ― | ― | ― | -55.00% | |
39 Underperform | AU$3.12M | -0.91 | -218.52% | ― | -30.80% | -38.95% | |
37 Underperform | AU$18.55M | -0.64 | -1476.79% | ― | -2.82% | 32.47% |
Atomo Diagnostics Ltd. Corporate Events
Atomo Diagnostics has scheduled the release of its Q2 FY26 financial results for Wednesday, 28 January 2026, and will host an investor and analyst webinar briefing on the same day at 2:00 pm AEDT, led by Managing Director and CEO John Kelly. The company is directing investors to pre-register online and use its Investor Hub to submit questions and comments in advance, underlining a continued focus on proactive engagement with the market and transparency around its financial and operational performance.
The most recent analyst rating on (AU:AT1) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Atomo Diagnostics Ltd. stock, see the AU:AT1 Stock Forecast page.
Atomo Diagnostics has secured an exclusive global licence from the Burnet Diagnostics Initiative for a novel liver function test that detects liver injury via alanine aminotransferase (ALT) using Atomo’s Pascal point-of-care cassette. The test, which is already substantively developed and undergoing evaluation by a large multinational pharmaceutical company in a US drug trial for drug-induced liver injury monitoring, positions Atomo to tap into a significant global market for rapid liver function screening and monitoring, including chronic liver diseases such as viral hepatitis, fatty liver and alcoholic liver disease. The agreement, which runs to the expiry of the underlying patents expected in 2044, builds on Atomo’s existing collaboration with Burnet and includes a $150,000 upfront licensing milestone payment plus performance-based regulatory milestone payments, while standard industry royalties will only commence once regulatory approvals are secured in key markets, lowering development risk and providing a clearer path to commercialisation.
The most recent analyst rating on (AU:AT1) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Atomo Diagnostics Ltd. stock, see the AU:AT1 Stock Forecast page.
Atomo Diagnostics Limited has secured a material purchase order worth $502,000 to supply its HIV self-test kits, manufactured under the Mylan brand, to an African country with funding from the Global Fund, with delivery planned for March. The deal underscores ongoing demand for Atomo’s HIV self-testing solutions in African markets and reinforces the company’s role in providing reliable, discreet diagnostic options in regions with significant HIV risk, supporting both its revenue base and its positioning in global rapid diagnostics.
The most recent analyst rating on (AU:AT1) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Atomo Diagnostics Ltd. stock, see the AU:AT1 Stock Forecast page.
Atomo Diagnostics Ltd. announced a change in the director’s interest, confirming the issuance of 1,000,000 unlisted options exercisable at $0.0115, expiring on June 30, 2028, to director Cheri Walker following shareholder approval. This grant highlights the company’s strategy to align leadership incentives with long-term stakeholder value creation.
The most recent analyst rating on (AU:AT1) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Atomo Diagnostics Ltd. stock, see the AU:AT1 Stock Forecast page.
Atomo Diagnostics Ltd. has announced the issuance of 3,100,000 unquoted equity securities in the form of options expiring on June 30, 2028, with an exercise price of $0.0115. This issuance is part of an employee incentive scheme and is not intended to be quoted on the ASX. The move is likely aimed at motivating and retaining key personnel, potentially impacting the company’s operational efficiency and market competitiveness.
The most recent analyst rating on (AU:AT1) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Atomo Diagnostics Ltd. stock, see the AU:AT1 Stock Forecast page.
Atomo Diagnostics Ltd. has responded to an ASX query regarding unusual trading activity in its securities, confirming it is unaware of any undisclosed price-sensitive information that could explain the recent changes in price and volume. The company asserts its compliance with ASX Listing Rules, specifically Rule 3.1, and states that its board has authorized the response.
The most recent analyst rating on (AU:AT1) stock is a Hold with a A$0.03 price target. To see the full list of analyst forecasts on Atomo Diagnostics Ltd. stock, see the AU:AT1 Stock Forecast page.
Atomo Diagnostics Ltd. announced the adoption of an amended constitution, as approved by its shareholders at the recent Annual General Meeting. This change reflects the company’s ongoing commitment to aligning its governance framework with its operational and strategic objectives, potentially impacting its market positioning and stakeholder engagement.
Atomo Diagnostics Limited announced the results of its 2025 Annual General Meeting, where all resolutions were passed by a poll. This announcement indicates a smooth decision-making process and reflects the company’s adherence to regulatory requirements, potentially strengthening stakeholder confidence.
Atomo Diagnostics Ltd. has released the MD & CEO’s address for their 2025 Annual General Meeting, highlighting the company’s ongoing commitment to innovation in the rapid diagnostic testing sector. This announcement underscores Atomo’s strategic focus on enhancing its market position by delivering cutting-edge diagnostic solutions, which is expected to positively impact its operations and stakeholder engagement.
Atomo Diagnostics Ltd. has made significant strides in the past year despite challenges in the global diagnostics sector. The company has advanced commercial partnerships, expanded international regulatory approvals, streamlined operations, and focused on high-value opportunities in infectious disease and rapid test applications. These efforts align with the growing trend towards decentralised, at-point-of-care, and self-testing solutions, reinforcing Atomo’s position in the market.
Atomo Diagnostics Ltd. has made significant commercial progress in Q1 FY26, highlighted by the submission of the FebriDx test for a CLIA waiver with the US FDA, following successful validation of the Pascal platform in clinical trials. The company has received substantial purchase orders from Lumos, totaling approximately $1 million, as part of their FebriDx agreement. Atomo’s HIV self-test has expanded its distribution channels, launching on Chemist Warehouse’s ecommerce site in Australia and receiving orders from USAID for Ukraine. Additionally, Atomo has secured $1.3 million in new capital to support ongoing business objectives, with a reported revenue of $680k for the quarter.
Atomo Diagnostics Limited announced it will release its Q1 FY26 results on October 29, 2025, followed by a webinar hosted by Managing Director & CEO, John Kelly. This announcement highlights Atomo’s ongoing commitment to transparency and engagement with analysts and investors, potentially impacting its market positioning and stakeholder relations positively.